Werewolf Therapeutics Faces Going Concern Doubt, Cuts 64% of Staff Amid Strategic Review

TL;DR

**HOWL is a high-risk bet on early-stage oncology assets, with a 'going concern' warning and massive layoffs signaling a desperate search for a lifeline.**

AI Summary

Werewolf Therapeutics, Inc. (HOWL) reported significant operational changes and clinical trial progress for the fiscal year ended December 31, 2025, while facing substantial doubt about its ability to continue as a going concern. The company initiated a strategic review process in February 2026, engaging Piper Sandler & Co. as its exclusive financial advisor, to explore options including a sale, merger, asset sale, or licensing arrangements. As part of a restructuring plan, Werewolf implemented a 64% workforce reduction, anticipating a one-time charge of approximately $4.1 million in Q1 2026 for employee separation benefits. Clinically, WTX-124, an IL-2 INDUKINE molecule, showed a 21% objective response rate as monotherapy in heavily pretreated metastatic cutaneous melanoma patients and 30% in non-primary resistant patients in Phase 1b expansion arms by December 2025. WTX-330, an IL-12 INDUKINE molecule, demonstrated favorable tolerability and antitumor activity, including one confirmed partial response with a 45% tumor reduction in metastatic gall bladder cancer by December 2025. The company has no products approved for commercial sale and has not generated any revenue from product sales, necessitating substantial additional funding.

Why It Matters

Werewolf Therapeutics' strategic review and significant workforce reduction underscore the intense capital demands and high-stakes nature of early-stage biopharmaceutical development. For investors, the 'going concern' warning signals extreme financial risk, making any investment highly speculative despite promising early clinical data for WTX-124 and WTX-330. Employees face job insecurity and the potential for further restructuring, while customers (future patients) await the uncertain outcome of drug development. The broader market will watch to see if Werewolf's PREDATOR platform can attract a strategic partner or buyer, highlighting the competitive pressures in the oncology immunotherapy space where many companies vie for breakthrough treatments.

Risk Assessment

Risk Level: high — The company explicitly states, 'We believe there is substantial doubt about our ability to continue as a going concern for at least twelve months from the date that these consolidated financial statements are issued.' This, coupled with a 64% workforce reduction and the engagement of Piper Sandler & Co. to explore strategic alternatives, indicates severe financial distress and an uncertain future for Werewolf Therapeutics.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment due to the 'going concern' warning and lack of product revenue. Monitor the strategic review process closely for any definitive agreements, as a successful acquisition or significant partnership could provide a much-needed capital infusion, but failure could lead to significant capital loss.

Financial Highlights

debt To Equity

Not Disclosed

revenue

$0

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

N/A

Key Numbers

• $39,559,339 — Aggregate market value of common stock held by non-affiliates (as of June 30, 2025, indicating a relatively small market capitalization for a biotech company)
• 48,596,817 — Shares of common stock outstanding (as of March 20, 2026)
• 64% — Workforce reduction (part of the restructuring plan to extend capital resources)
• $4.1 million — Estimated one-time charge for employee separation benefits (anticipated in Q1 2026 due to the reduction in force)
• 21% — Objective response rate for WTX-124 monotherapy (in heavily pretreated patients with advanced or metastatic cutaneous melanoma by December 2025)
• 30% — Objective response rate for WTX-124 monotherapy (in patients not primary resistant to immunotherapy by December 2025)
• 45% — Reduction in tumor target lesions for WTX-330 (in one confirmed partial response in metastatic gall bladder cancer by December 2025)

Key Players & Entities

• Werewolf Therapeutics, Inc. (company) — registrant
• Piper Sandler & Co. (company) — exclusive financial advisor for strategic review
• Merck & Co., Inc. (company) — partner for KEYTRUDA combination therapy
• Jazz Pharmaceuticals Ireland Limited (company) — licensee of JZP898 (formerly WTX-613)
• Harpoon Therapeutics, Inc. (company) — licensor of patent rights
• WTX-124 (company) — most advanced product candidate (IL-2 INDUKINE molecule)
• WTX-330 (company) — second most advanced product candidate (IL-12 INDUKINE molecule)
• KEYTRUDA (company) — anti-PD-1 therapy (pembrolizumab)
• PREDATOR platform (company) — proprietary drug discovery platform
• Nasdaq Global Select Market (regulator) — exchange where common stock is registered

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company faces substantial doubt about its ability to continue as a going concern due to its lack of product revenue and significant ongoing research and development expenses. This uncertainty is amplified by the initiation of a strategic review process in February 2026, exploring options like a sale or merger, which may not result in a transaction that enhances stockholder value.
• Restructuring and Workforce Reduction [high — operational]: A significant restructuring plan was adopted in February 2026, including a 64% workforce reduction. This resulted in an estimated one-time charge of approximately $4.1 million for employee separation benefits in Q1 2026, impacting operational capacity and potentially incurring additional costs.
• Clinical Trial and Regulatory Approval Risks [high — regulatory]: The company's product candidates, WTX-124 and WTX-330, are still in clinical development with no products approved for commercial sale. Success is dependent on demonstrating safety and efficacy in ongoing trials and obtaining regulatory approvals, which are inherently uncertain and time-consuming processes.
• Dependence on Strategic Alternatives [high — market]: The company's future is heavily reliant on the outcome of its strategic review process initiated in February 2026. The success of this process, which could lead to a sale, merger, or licensing, is not guaranteed and could significantly impact the company's trajectory and stockholder value.
• Need for Substantial Additional Funding [high — financial]: Werewolf Therapeutics has not generated any revenue from product sales and requires substantial additional funding to continue its operations and development programs. Failure to secure this funding could jeopardize its ability to continue as a going concern.

Industry Context

The biopharmaceutical industry, particularly in oncology, is highly competitive and innovation-driven. Companies are focused on developing novel immunotherapies and targeted treatments to address unmet medical needs. The landscape is characterized by significant R&D investment, long development timelines, and high regulatory hurdles. Emerging technologies like conditional activation and bispecific antibodies are gaining traction for their potential to improve efficacy and safety profiles.

Regulatory Implications

Werewolf Therapeutics operates within a highly regulated environment. The development of its product candidates, WTX-124 and WTX-330, is subject to rigorous clinical trial requirements and stringent review processes by regulatory bodies like the FDA. Failure to demonstrate safety and efficacy in clinical trials or to navigate the approval process successfully poses a significant risk to the company's future.

What Investors Should Do

1. Monitor the strategic review process closely.
2. Evaluate clinical trial data for WTX-124 and WTX-330.
3. Assess the company's cash runway and funding needs.
4. Consider the impact of the workforce reduction.

Key Dates

• 2025-12-31: Fiscal year end — Provided clinical trial data for WTX-124 and WTX-330, showing objective response rates and tumor reduction, but also highlighting the early stage of development.
• 2026-02-01: Strategic review process initiated — Engaged Piper Sandler & Co. to explore strategic alternatives including sale, merger, or licensing, signaling a critical juncture for the company's future.
• 2026-02-01: Restructuring plan adopted — Included a 64% workforce reduction to extend capital resources and align with the pursuit of strategic alternatives.
• 2026-03-20: Shares of common stock outstanding reported — 48,596,817 shares outstanding as of this date, providing a baseline for market capitalization calculations.
• 2026-06-30: Aggregate market value of common stock held by non-affiliates reported — $39,559,339, indicating a relatively small market capitalization for a biotech company at that time.

Glossary

INDUKINE

A proprietary molecule developed by Werewolf Therapeutics that is a conditionally activated Interleukin (IL-2 or IL-12) designed to stimulate the immune system selectively in the tumor microenvironment. (Represents the company's core technology platform for its most advanced product candidates, WTX-124 and WTX-330.)

PREDATOR platform

Werewolf Therapeutics' proprietary platform used to design conditionally activated molecules, including INDUKINE and INDUCER molecules, aiming to activate immune responses selectively in the tumor microenvironment. (Underpins the company's drug development strategy and its ability to create novel immunotherapies.)

Tumor Microenvironment (TME)

The complex ecosystem surrounding a tumor, including immune cells, stromal cells, blood vessels, and signaling molecules, which can influence tumor growth and response to therapy. (Werewolf's INDUKINE molecules are designed to activate specifically within the TME, aiming to enhance efficacy and reduce systemic side effects.)

Going Concern

An accounting principle that assumes a company will continue to operate for the foreseeable future. If there is substantial doubt about this, it must be disclosed. (The company has disclosed substantial doubt about its ability to continue as a going concern, highlighting significant financial risks.)

Objective Response Rate (ORR)

A measure of how well a cancer treatment works, defined as the percentage of patients whose tumors shrink or disappear completely in response to treatment. (Key metric reported for WTX-124, indicating early clinical efficacy signals in melanoma patients.)

Partial Response (PR)

A measure of tumor shrinkage in response to treatment, typically defined as at least a 30% reduction in the sum of the diameters of target lesions. (Reported for WTX-330 in a patient with metastatic gall bladder cancer, indicating antitumor activity.)

Year-Over-Year Comparison

The company's financial condition has significantly deteriorated, leading to substantial doubt about its ability to continue as a going concern, a critical disclosure not present in prior filings. The initiation of a strategic review process and a 64% workforce reduction highlight a major shift in operational strategy and financial pressure. While clinical progress with WTX-124 and WTX-330 is noted, the lack of revenue and the need for substantial funding remain persistent challenges.

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share HOWL The Nasdaq Gl
• $4.1 m — and related benefits, of approximately $4.1 million, most of which is anticipated to

Filing Documents

• howl-20251231.htm (10-K) — 2049KB
• a12312025ex231.htm (EX-23.1) — 5KB
• a12312025ex311.htm (EX-31.1) — 10KB
• a12312025ex312.htm (EX-31.2) — 10KB
• a12312025ex321.htm (EX-32.1) — 7KB
• howl-20251231_g1.jpg (GRAPHIC) — 37KB
• howl-20251231_g2.jpg (GRAPHIC) — 54KB
• 0001785530-26-000006.txt ( ) — 8504KB
• howl-20251231.xsd (EX-101.SCH) — 56KB
• howl-20251231_cal.xml (EX-101.CAL) — 88KB
• howl-20251231_def.xml (EX-101.DEF) — 234KB
• howl-20251231_lab.xml (EX-101.LAB) — 708KB
• howl-20251231_pre.xml (EX-101.PRE) — 494KB
• howl-20251231_htm.xml (XML) — 861KB

Business

Business 3 Item 1A.

Risk Factors

Risk Factors 34 Item 1B. Unresolved Staff Comments 90 Item 1C. Cybersecurity 90 Item 2.

Properties

Properties 90 Item 3.

Legal Proceedings

Legal Proceedings 90 Item 4. Mine Safety Disclosures 90 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 91 Item 6. Reserved 91 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 92 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 102 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 102 Item 9. Change in and Disagreements with Accountants on Accounting and Financial Disclosure 102 Item 9A.

Controls and Procedures

Controls and Procedures 102 Item 9B. Other Information 103 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 103 PART III Item 10. Directors, Executive Officers and Corporate Governance 103 Item 11.

Executive Compensation

Executive Compensation 106 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 113 Item 13. Certain Relationships and Related Transactions, and Director Independence 115 Item 14. Principal Accountant Fees and Services 116 PART IV Item 15. Exhibit and Financial Statement Schedules 117 Item 16. Form 10-K Summary 117

SIGNATURES

SIGNATURES EXHIBIT INDEX Table of Contents References to Werewolf Throughout this Annual Report on Form 10-K, or Annual Report, the "Company," "Werewolf," "Werewolf Therapeutics," "we," "us," "our," and similar references, except where the context requires otherwise, refer to Werewolf Therapeutics, Inc. and its consolidated subsidiary, and "board of directors" refers to the board of directors of Werewolf Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements and Industry Data This Annual Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act, that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. The words "aim," "anticipate," "believe," "contemplate," "continue," "could," "design," "designed to," "engineered," "estimate," "expect," "goal," "intend," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "promise," "project," "should," "target," "will," "would," or the negative of these words or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about: the initiation, timing, progress and results of our research and development programs, preclinical studies and ongoing and planned clinical trials, including the anticipated timing of data announcements; our estimates regarding expenses, capital requirements, need for additional financing and the period over which we believe our existing cash and cash eq

Business

Item 1. Business Company Overview We are an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. We are leveraging our proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our molecules, which we refer to as INDUKINE and INDUCER molecules, are intended to activate selectively in the tumor microenvironment, or TME. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12), respectively, INDUKINE molecules for the treatment of multiple tumor types. We are also utilizing this PREDATOR platform know-how and expertise to develop conditionally activated immune cell engagers. Immune cell engagers, such as T cell engagers, are typically bispecific antibodies that redirect immune cells to cancer cells via engagement with tumor associated cell surface antigens, leading to immune cell mediated killing of the cancer cells. We have provided initial preclinical data for our proprietary INDUCER T cell engager molecules demonstrating that our PREDATOR masking technology silenced peripheral activity and prevented cytokine release. In February 2026, we adopted a restructuring plan to extend our capital resources in connection with initiating a process to explore a full range of strategic alternatives to advance our promising platform and drug development pipeline to maximize stockholder value. We have engaged Piper Sandler & Co, or Piper Sandler, to serve as exclusive financial advisor to assist in the strategic review process. Measures contemplated during the strategic review process may include, among other options, a sale of our company, a business combination or merger, a sale

View Full Filing

View this 10-K filing on SEC EDGAR